- Oral presentation
- Open Access
Brace treatment can change aesthetics in Adolescent Idiopathic Scoliosis (AIS) patients
© Zaina et al; licensee BioMed Central Ltd. 2009
- Published: 15 January 2009
- Public Health
- Adolescent Idiopathic Scoliosis
- Idiopathic Scoliosis
- Definitive Result
- Clinical Scale
Aesthetics is a main goal both of conservative and surgical treatment in AIS. Previously we developed and validated a clinical scale, the Aesthetic Index (AI), to measure aesthetic impairment and changes during treatment.
To verify the efficacy of bracing on aesthetics in AIS.
Thirty four consecutive patients, age 13.2 ± 3.7, initial Cobb Angle 30 ± 12°, ATR 10 ± 4° Bunnel, 11 males.
Patients with at least 5/6 score of AI were included. All of them had a brace prescription (18 to 23 h per day). After 6 months, AI was measured again, and pre-post scores compared. The Wilcoxon test was performed. 11 of these patients already concluded treatment and definitive results are reported.
At the beginning, median AI was 6 (95% IC 5–6), after 6 months of brace AI score decreased to 2 (95% IC 0–6) (p < 0.05). In the final subgroup results, the effect of the brace was the same (from 6 to 3). After 6 months, we did not find any difference in the results according to the hours of brace wearing or to the type of exercises performed.
Use of a brace for just 6 months, will improve aesthetics. This is evident even in high aesthetic impact scoliosis. Completing brace treatment can guarantee the maintenance of achieved results.
- Zaina F, Negrini S, Monticone M, Paroli C, Aulisa A: Repeatability of the Aesthetic Index for adolescent scoliosis idiopathic evaluation. Scoliosis. 2007, 2 (Suppl 1): S46. 10.1186/1748-7161-2-S1-S46.View ArticleGoogle Scholar
- Negrini S, Marchini G: Efficacy of the symmetric, patient-oriented, rigid, three-dimensional, active (SPoRT) concept of bracing for scoliosis: a prospective study of the Sforzesco versus Lyon brace. Eura Medicophys. 2007, 43 (2): 171-81.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.